Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Cancer Research Center of Hawaii
mi
from
Honolulu, HI
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Cancer Research Center of Hawaii
mi
from
Honolulu, HI
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Northwestern Cancer Center
mi
from
Chicago, IL
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Northwestern Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Montefiore Medical Center
mi
from
Bronx, NY
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Montefiore Medical Center
mi
from
Bronx, NY
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia
mi
from
Philadelphia, PA
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Pennsylvania Oncology Hematology Associates, Incorporated - Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Thomas Street Health Center
mi
from
Houston, TX
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Thomas Street Health Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Baylor College of Medicine
mi
from
Houston, TX
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Virginia Mason Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Rebecca and John Moores UCSD Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
USC/Norris Comprehensive Cancer Center and Hospital
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
University of Miami Sylvester Comprehensive Cancer Center - Miami
mi
from
Miami, FL
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated:  4/4/2016
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma
Status: Enrolling
Updated: 4/4/2016
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Phase II Study of Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Status: Enrolling
Updated:  4/6/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Phase II Study of Alemtuzumab (Campath-1H) Monoclonal Antibody in Patients With Relapsed and Resistant Classical Hodgkin's Disease
Status: Enrolling
Updated: 4/6/2016
UT MD Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of PNT2258 in Patients With Advanced Solid Tumors
A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  4/11/2016
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study of PNT2258 in Patients With Advanced Solid Tumors
A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 4/11/2016
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)
Exploratory Study to Evaluate the Safety and Efficacy of CD5789 in Subjects With Early Stage Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated:  4/11/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
CD5789 in Early Cutaneous T-Cell Lymphoma (CTCL)
Exploratory Study to Evaluate the Safety and Efficacy of CD5789 in Subjects With Early Stage Cutaneous T-Cell Lymphoma
Status: Enrolling
Updated: 4/11/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols
Status: Enrolling
Updated:  4/15/2016
Florida Cancer Specialists
mi
from
Sarasota, FL
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols
Status: Enrolling
Updated: 4/15/2016
Florida Cancer Specialists
mi
from
Sarasota, FL
Click here to add this to my saved trials
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols
Status: Enrolling
Updated:  4/15/2016
Sarah Cannon Research Institute
mi
from
Nashville, TN
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols
Status: Enrolling
Updated: 4/15/2016
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols
Status: Enrolling
Updated:  4/15/2016
Sarah Cannon Research UK
mi
from
London,
A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
An Open Label, Single-Arm Rollover Study for Subjects Who Participated In Other Romidepsin Protocols
Status: Enrolling
Updated: 4/15/2016
Sarah Cannon Research UK
mi
from
London,
Click here to add this to my saved trials
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated:  4/18/2016
Clearview Cancer Institute
mi
from
Huntsville, AL
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated: 4/18/2016
Clearview Cancer Institute
mi
from
Huntsville, AL
Click here to add this to my saved trials
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated:  4/18/2016
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated: 4/18/2016
Horizon Oncology Research, Inc.
mi
from
Lafayette, IN
Click here to add this to my saved trials
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated:  4/18/2016
Hackensack UMC
mi
from
Hackensack, NJ
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated: 4/18/2016
Hackensack UMC
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated:  4/18/2016
The West Clinic, PC
mi
from
Memphis, TN
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated: 4/18/2016
The West Clinic, PC
mi
from
Memphis, TN
Click here to add this to my saved trials
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated:  4/18/2016
Universitätsklinik Ulm
mi
from
Ulm,
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 1b, Multi-center, Open Label, Study to Determine the Safety and Activity of CC-292 in Combination With Rituximab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma.
Status: Enrolling
Updated: 4/18/2016
Universitätsklinik Ulm
mi
from
Ulm,
Click here to add this to my saved trials
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated:  4/18/2016
Yale University
mi
from
New Haven, CT
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated: 4/18/2016
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated:  4/18/2016
Northeast Georgia Cancer Care
mi
from
Athens, GA
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated: 4/18/2016
Northeast Georgia Cancer Care
mi
from
Athens, GA
Click here to add this to my saved trials
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated:  4/18/2016
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated: 4/18/2016
John Theurer Cancer Center at the Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated:  4/18/2016
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated: 4/18/2016
Hematology Oncology Associates of Northern NJ
mi
from
Morristown, NJ
Click here to add this to my saved trials
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated:  4/18/2016
Columbia University Medical Center/Center for Lymphiod Malignancies
mi
from
New York, NY
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated: 4/18/2016
Columbia University Medical Center/Center for Lymphiod Malignancies
mi
from
New York, NY
Click here to add this to my saved trials
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated:  4/18/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated: 4/18/2016
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated:  4/18/2016
The Mayo Clinic
mi
from
Rochester, MN
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated: 4/18/2016
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated:  4/18/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)
Status: Enrolling
Updated: 4/18/2016
Washington University School of Medicine
mi
from
St. Louis, MO
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Beverly Hills, CA
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Fountain Valley, CA
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Oxnard, CA
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Oxnard, CA
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Washington,
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Washington,
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Boynton Beach, FL
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Brooksville, FL
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Brooksville, FL
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Gainesville, FL
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Gainesville, FL
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Titusville, FL
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Titusville, FL
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Joliet, IL
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Joliet, IL
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Lafayette, IN
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Lafayette, IN
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Muncie, IN
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Muncie, IN
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Dubuque, IA
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Dubuque, IA
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Paducah, KY
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Paducah, KY
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
York, ME
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
York, ME
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Jackson, MS
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Jackson, MS
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Chesterfield, MO
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Cherry Hill, NJ
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  4/18/2016
Pharmatech Oncology Study Site
mi
from
Phillipsburg, NJ
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 4/18/2016
Pharmatech Oncology Study Site
mi
from
Phillipsburg, NJ
Click here to add this to my saved trials